176 related articles for article (PubMed ID: 27798860)
1. Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?
Damaskos C; Garmpis N; Valsami S; Spartalis E; Antoniou EA; Tomos P; Karamaroudis S; Zoumpou T; Pergialiotis V; Stergios K; Michaelides C; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2016 Oct; 36(10):5019-5024. PubMed ID: 27798860
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma.
Spartalis E; Athanasiadis DI; Chrysikos D; Spartalis M; Boutzios G; Schizas D; Garmpis N; Damaskos C; Paschou SA; Ioannidis A; Tsourouflis G; Dimitroulis D; Nikiteas NI
Anticancer Res; 2019 Mar; 39(3):1119-1127. PubMed ID: 30842140
[TBL] [Abstract][Full Text] [Related]
3. Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations?
Garmpis N; Damaskos C; Garmpi A; Dimitroulis D; Spartalis E; Margonis GA; Schizas D; Deskou I; Doula C; Magkouti E; Andreatos N; Antoniou EA; Nonni A; Kontzoglou K; Mantas D
Anticancer Res; 2017 Oct; 37(10):5355-5362. PubMed ID: 28982843
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride.
Adler JT; Hottinger DG; Kunnimalaiyaan M; Chen H
J Surg Res; 2010 Apr; 159(2):640-4. PubMed ID: 19394967
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase Inhibitors and Papillary Thyroid Cancer.
Spartalis E; Kotrotsios K; Chrysikos D; Spartalis M; Paschou SA; Schizas D; Tsamakis K; Dimitroulis D; Troupis T; Nikiteas N
Curr Pharm Des; 2021; 27(18):2199-2208. PubMed ID: 33308111
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
[TBL] [Abstract][Full Text] [Related]
7. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics in Medullary Thyroid Cancer: From Pathogenesis to Targeted Therapy.
Vitale G; Dicitore A; Messina E; Sciammarella C; Faggiano A; Colao A
Recent Pat Anticancer Drug Discov; 2016; 11(3):275-82. PubMed ID: 27306881
[TBL] [Abstract][Full Text] [Related]
9. Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.
Ning L; Greenblatt DY; Kunnimalaiyaan M; Chen H
Oncologist; 2008 Feb; 13(2):98-104. PubMed ID: 18305053
[TBL] [Abstract][Full Text] [Related]
10. New drugs for medullary thyroid cancer: new promises?
Spitzweg C; Morris JC; Bible KC
Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer.
Feng W; Zhang B; Cai D; Zou X
Cancer Lett; 2014 Jun; 347(2):183-90. PubMed ID: 24534202
[TBL] [Abstract][Full Text] [Related]
13. Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
Damaskos C; Garmpis N; Valsami S; Kontos M; Spartalis E; Kalampokas T; Kalampokas E; Athanasiou A; Moris D; Daskalopoulou A; Davakis S; Tsourouflis G; Kontzoglou K; Perrea D; Nikiteas N; Dimitroulis D
Anticancer Res; 2017 Jan; 37(1):35-46. PubMed ID: 28011471
[TBL] [Abstract][Full Text] [Related]
14. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K; Simeakis G; Karapanou O; Alevizaki M
Eur J Endocrinol; 2022 Sep; 187(3):R53-R63. PubMed ID: 35895692
[TBL] [Abstract][Full Text] [Related]
15. The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence.
Moschos MM; Dettoraki M; Androudi S; Kalogeropoulos D; Lavaris A; Garmpis N; Damaskos C; Garmpi A; Tsatsos M
Anticancer Res; 2018 Jul; 38(7):3817-3824. PubMed ID: 29970501
[TBL] [Abstract][Full Text] [Related]
16. Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Mitsiades CS; Poulaki V; McMullan C; Negri J; Fanourakis G; Goudopoulou A; Richon VM; Marks PA; Mitsiades N
Clin Cancer Res; 2005 May; 11(10):3958-65. PubMed ID: 15897598
[TBL] [Abstract][Full Text] [Related]
17. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer.
Takai N; Kira N; Ishii T; Nishida M; Nasu K; Narahara H
Asian Pac J Cancer Prev; 2011; 12(3):575-80. PubMed ID: 21627347
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone deacetylase in thyroid cancer.
Russo D; Durante C; Bulotta S; Puppin C; Puxeddu E; Filetti S; Damante G
Expert Opin Ther Targets; 2013 Feb; 17(2):179-93. PubMed ID: 23234477
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
20. Current Guidelines for Management of Medullary Thyroid Carcinoma.
Kim M; Kim BH
Endocrinol Metab (Seoul); 2021 Jun; 36(3):514-524. PubMed ID: 34154310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
